

(7)

## REISSUE LITIGATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:  
U.S. Patent No. 5,750,338

Mark L. Collins *et al.*

Reissue Serial No. 09/533,906

Reissue Application Filed: March 8, 2000

For: TARGET AND BACKGROUND  
CAPTURE METHODS WITH  
AMPLIFICATION FOR AFFINITY  
ASSAYS

Group Art Unit: 1634

Examiner: Unassigned

PROTEST UNDER 37 C.F.R. § 1.291**ATTENTION: REISSUE LITIGATION BOX 7**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.291, the following protest is submitted for consideration. This protest has been served on the reissue applicants in accordance with 37 C.F.R. § 1.248, as indicated by the attached proof of service.

---

CERTIFICATE OF DELIVERY

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being hand delivered to Group Art Unit 1634 on the date shown below, addressed to the Commissioner for Patents, Reissue Litigation Box 7, Washington, D.C. 20231.

---

*8/2/00*  
Date of Delivery

Thinh Nguyen  
Name of Person Delivering Paper

*Thinh Nguyen*  
Signature of Person Delivering Paper

## TABLE OF CONTENTS

<b>I.</b>	<b>ALL CLAIMS OF THE REISSUE APPLICATION ARE OBVIOUS OVER PRIOR ART ANTEDATING DECEMBER 21, 1987</b>	1
A.	Isolation Of Target Polynucleotide From A Sample By Capture On A Solid Support Is Disclosed In The Prior Art	3
B.	Amplification Of Target Polynucleotides Is Disclosed In The Prior Art	4
C.	The Prior Art Provides Motivation To Combine Target Capture On A Solid Support With Amplification Of The Isolated Polynucleotide	6
D.	Summary And Application Of The Prior Art To The Claims	10
<b>II.</b>	<b>ARGUMENTS MADE BY THE REISSUE APPLICANTS IN THE PROSECUTION OF THE '338 PATENT CANNOT OVERCOME AN OBVIOUSNESS REJECTION</b>	15
<b>III.</b>	<b>CLAIMS 1-8, 10-14, 24-52, 55, 58 AND 59 ARE ANTICIPATED BY PRIOR ART ANTEDATING DECEMBER 21, 1987</b>	21
<b>IV.</b>	<b>ALL NEWLY PRESENTED CLAIMS MUST BE REJECTED BECAUSE THEY ARE NOT SUPPORTED BY THE DISCLOSURES OF THE '338 PATENT</b>	31
	<b>CONCLUSION</b>	37

REISSUE LITIGATION

**REMARKS**

The following remarks present arguments supporting the conclusion that there is no basis for reissue of U.S. Patent No. 5,750,338 because:

- All claims are invalid as obvious under 35 U.S.C. § 103 (Sections I, II);
- Many claims are invalid as anticipated under 35 U.S.C. § 102 (Section III); and
- The new claims added to the reissue application should be rejected under the “written description” requirement of 35 U.S.C. § 112, first paragraph and the requirement of 35 U.S.C. § 251 that the reissue application be for the “invention disclosed in the original patent” (Section IV).

Protestor respectfully requests that the Examiner consider these remarks, and the accompanying declaration of Dr. Michael Harpold in support of the remarks contained in Sections I, II, and III, in examining reissue application no. 09/533,906.

**I. ALL CLAIMS OF THE REISSUE APPLICATION ARE OBVIOUS OVER PRIOR ART ANTEDATING DECEMBER 21, 1987.**

The reissue application under protest contains 59 claims. Claims 1-40 are essentially unchanged from the correspondingly numbered claims of the '338 patent. New claims 41-59 have been added in this reissue application. All the claims are directed to a process (or a kit for carrying out such process) for amplifying and/or detecting a target polynucleotide contained in a sample.

The process claimed in the reissue application involves three essential steps: contacting the sample with a solid support that binds the target polynucleotide; separating the support and bound target polynucleotide from the sample; and amplifying the target polynucleotide. These

## REISSUE LITIGATION

three steps characterize the claimed invention, although additional steps and limitations are added in various claims. Claims are also directed to kits comprising means for carrying out these steps.

Protestor sets forth below reasons why the claimed invention would have been obvious prior to the filing date. Protestor also submits herewith the declaration of Dr. Michael Harpold, which supports these remarks. Dr. Harpold's declaration sets forth the general state of the art prior to the filing date (¶ 5); his view of the level of ordinary skill in the art of molecular biology at the filing date (¶ 6); a discussion of specific references relevant to the claimed invention (¶¶ 8-10); his conclusion that the claimed invention would have been obvious to one of ordinary skill in the art (¶ 11); and his observations on the declaration of Dr. David Persing, which was submitted by reissue applicants during the prosecution of the '338 patent (¶¶ 12, 13).

Each of the steps recited in the claimed method is disclosed in the prior art. Contrary to representations made by the reissue applicants during prosecution of the '338 patent, the prior art provided ample motivation to one skilled in the art at the filing date<sup>1</sup> to combine these steps.

Consequently, the claims are unpatentable under 35 U.S.C. §103.

---

<sup>1</sup> For purposes of this section, Protestor has relied on prior art having effective dates earlier than December 21, 1987, the filing date of U.S. application no. 136,920. Although the '338 patent recites an earliest priority date of October 23, 1986, *i.e.* the filing date of U.S. application no. 922,155, the claims in the reissue application cannot be entitled to that date since the '155 application contains no disclosure whatsoever of amplification following target capture. Reissue applicants have implicitly acknowledged that they are not entitled to the priority of the '155 application (see, p.6 of the Preliminary Amendment filed with the reissue application, where applicants treat December, 1987 as the relevant prior art date).

**A. Isolation Of Target Polynucleotide From A Sample By Capture On A Solid Support Is Disclosed In The Prior Art.**

*U.S. Patent No. 4,672,040 (Josephson)* discloses contacting capture probes immobilized on dispersible magnetic beads with a sample containing complementary target polynucleotides and separating the support and bound polynucleotides from the target, *i.e.*, the first two steps of the presently claimed process. In particular, *Josephson* states:

Specific DNA or RNA fragments can also be isolated from genomic and cloned DNA by immobilization of a known probe to the magnetic particles and placing the coupled particles in contact with a mixture of nucleic acid fragments, including the desired species. After hybridization the particles may be magnetically separated from unbound materials, washed, and the hybridized molecules isolated. (Col. 19, ll. 3-10)

The foregoing statement directly contradicts the assertion in the '338 patent that, "...[M]agnetic particles have not been suggested as retrievable supports for target capture and background removal" (col. 4, ll. 27-29). *Josephson* further states that the magnetic particles can be used in binding assays (col. 16, ll. 13 *et seq.*). Clearly, such binding assays include nucleic acid hybridization assays since the use of dispersible capture probes for nucleic acid hybridization is taught, for example, in Section 6.6 (col. 18, ll. 29 *et seq.*).

*U.S. Patent No. 4,554,088 (Whitehead)* discloses the use of single-stranded nucleic acid bound to dispersible magnetic beads to isolate complementary nucleic acid from a sample. The nucleic acid capture probe immobilized on a magnetic bead is employed as a "ligand" to bind its soluble "ligate", which is the complementary nucleic acid in the sample (see Table III, col. 17). The magnetic beads bound to target nucleic acid are magnetically separated from the sample and unbound (non-target) species are removed by washing (col. 17, ll. 36-40).

REISSUE LITIGATION

*Polsky-Cynkin et al., Clin. Chem. 31/9:1438-1443(1985)* describe DNA hybridization assays in which target DNA is captured by a complementary probe affixed to a solid support. The captured target DNA on the solid support is separated from the sample and detected with a radiolabeled probe. The solid supports employed included agarose beads (*i.e.*, retrievable supports), polypropylene test tubes and polypropylene solid-phase receptacles (*e.g.*, see p. 1439).

*U.S. Patent No. 4,563,419 (Ranki)* discloses a hybridization assay in which target nucleic acid is isolated from a sample by hybridizing it to a complementary capture probe immobilized on a solid support (nitrocellulose filter) and separated from the sample by washing. The captured target polynucleotide is detected with a labeled probe.

**B. Amplification Of Target Polynucleotides Is Disclosed In The Prior Art.**

The reissue application defines the term "amplify" in extremely broad terms. The definition includes any process by which copies of target polynucleotide are produced or by which other molecules (sometimes referred to as "reporter" molecules) are produced by virtue of the presence of the target polynucleotide (col. 2, ll. 9-19).

The applicants' broad definition encompasses processes such as cloning, cell-free translation and synthesis of cDNA from mRNA, all of which were basic techniques of molecular biology in December 1987. The Examiner will appreciate that many references describing such forms of amplification could be cited as prior art. New claims 41-59, which were added in the reissue application, limit the amplification step to an *in vitro* amplification process in an attempt

REISSUE LITIGATION

to avoid what reissue applicants characterize as “prior art from an earlier period of molecular biology”<sup>2</sup> (Preliminary Amendment, p.5). Consequently, here Protestor will focus on prior art references disclosing *in vitro* amplification.

The specification of the ‘338 patent discloses only three types of *in vitro* amplification: non-specific enzymatic amplification primed by random hexamer primers (Examples 5 and 6); non-specific amplification using Q $\beta$  replicase enzyme (Example 7); and non-specific transcription of DNA by *E. coli* RNA polymerase (Example 4). To the extent that any of these might be effective to replicate target polynucleotide, they are each disclosed in the prior art.

The use of random hexamer oligonucleotide primers to initiate non-specific enzymatic reproduction of polynucleotides is disclosed in *Feinberg et al., Anal. Biochem. 132:6-13 (1983)*.

Example 7 of the ‘338 patent purports to disclose non-specific, exponential amplification of isolated polynucleotide using the enzyme Q $\beta$  replicase. To the extent that the reissue applicants rely on the described Q $\beta$  replicase amplification to support the claims, they acknowledge, at col. 32, ll. 16-17, that this form of amplification is taught in the prior art (*Blumenthal, Proc. Natl. Acad. Sci. U.S.A. 77:2601 (1980)*).

---

<sup>2</sup> Cell-free translation and cDNA synthesis are both *in vitro* processes, as are the initial steps of many cloning procedures. Therefore, the limitation in new claims 41-59 to *in vitro* amplification does not avoid the effect of prior art references teaching such methods. Having chosen to define “amplify” broadly, applicants cannot now seek a narrower definition in an attempt to avoid the prior art. That is, the patentee cannot now offer an interpretation that would alter the record (the specification) on which the public is entitled to rely. *Vitronics Corp. v. Conceptronic Inc.*, 90 F.3d 1576, 1582-1583, 39 USPQ2d 1573, 1577 (Fed. Cir. 1996).

REISSUE LITIGATION

The use of *E. coli* RNA polymerase core enzyme to transcribe DNA into RNA *in vitro* was known in the prior art, as acknowledged by applicants in their citation to R. Burgess in *RNA Polymerase*, *Cold Spring Harbor Press*, pp. 69-100 (1976) ('338 patent, col. 30, ll. 62-64).

In addition to the three forms of non-specific *in vitro* amplification disclosed in the '338 patent specification, the prior art discloses other forms of *in vitro* amplification. The well-known polymerase chain reaction (PCR), which is an *in vitro* exponential amplification method, is disclosed, for example, in *U.S. Patent No. 4,683,202 (Mullis)*. A method of amplifying RNA sequences by strand displacement synthesis is disclosed in *Gaubatz et al., Biochim. Biophys. Acta*, 825:175-187 (1985)<sup>3</sup>.

**C. The Prior Art Provides Motivation To Combine Target Capture On A Solid Support With Amplification Of The Isolated Polynucleotide.**

Contrary to arguments made during prosecution of the '338 patent, the prior art explicitly suggests combining the isolation of a target polynucleotide from a sample by capture on a solid support with subsequent amplification of the isolated polynucleotide.

In *Methods of Gene Isolation* (*Brown et al., Ann. Rev. Biochem.*, 43:667-693 (1974)), the authors review various methods for isolating nucleic acid sequences of interest for analysis, e.g. by molecular hybridization assay. The authors describe different methods of purifying

---

<sup>3</sup> See Section III for a more detailed discussion of this reference.

REISSUE LITIGATION

polynucleotides of interest from samples. In the section entitled "Polynucleotides Fixed to Insoluble Matrices" they state:

ssDNA components can be purified by fixing complementary RNA or DNA molecules to some kind of insoluble support and circulating the soluble DNA mixture through the affinity column. Large amounts of sequence-specific DNA have been purified from mixtures of phage and bacterial DNAs by circulating the denatured DNAs through columns containing one of the DNAs adsorbed to nitrocellulose. (p. 673-674)

In their "CONCLUDING REMARKS," the authors teach the desirability of combining target isolation with a subsequent amplification step, particularly where the target polynucleotide is present in the initial sample at low concentration.

**Clearly, purification of important structural genes will have to be coupled with some method in which a small amount of a given gene can be increased enormously in amount. After purification has enriched the gene sequence about a thousandfold the remaining DNA would be amplified hundreds- to thousandsfold in amount...The amplification step might be carried out in vitro by an efficient DNA polymerase, which would replicate faithfully each molecule of DNA many times.** (p. 687) (emphasis added)

The description of the amplification step in the '338 patent is a virtual echo of the emphasized passage above:

In the situation where the target is a polynucleotide, additional target, or target-like molecules, or molecules subject to detecting can be made enzymatically with DNA or RNA polymerases or transcriptases. (col. 2, ll. 16-19) (emphasis added)

REISSUE LITIGATION

Thus, *Brown et al.* provide a clear direction to combine solid phase target capture with amplification to provide large quantities of target polynucleotide for detection. This goes to the very core of the reissue applicants' claimed "invention" because during prosecution applicants' attorney stated, "The invention advances nucleic acid hybridization methods by combining target purification methods with target amplification methods." (Preliminary Amendment and Response to Restriction Requirement, filed December 5, 1995 in U.S. application no. 08/283,080 ("the '080 application").

The reissue applicants cannot effectively argue that the *Brown et al.* article may not have provided all the enabling technical details for carrying out the steps of the claimed process. Both solid phase target capture and amplification methods (as described in the '338 patent) were well known to those skilled in the art by December 21, 1987, as shown by the references cited in Sections A and B above.

Additional motivation to combine target capture on a solid support with amplification is provided by *Arsenyan et al.*, *Gene* 11:97-108 (1980)<sup>4</sup>. This reference describes the isolation and amplification of rat liver 5S RNA genes. The authors state:

In order to study the arrangement of genes it is necessary to isolate **amplified** homogeneous DNA sequences with spacer regions. There are two principal ways of isolating such sequences: (a) "Shotgun" cloning of total genomic DNA, followed by a colony hybridization with labelled RNA or cDNA...Since most of the eukaryotic genes are found as single copies in a genome, the screening of individual recombinants is difficult. (b) A **preliminary enrichment of such genes, followed by a bacterial cloning.** (p. 97, col.2 to p.98, col.1, emphasis added)

---

<sup>4</sup> See Section III for additional discussion of this reference.

REISSUE LITIGATION

This reference shows that the art understood that when additional sensitivity and specificity were needed, the combination of preliminary enrichment and amplification would yield better results. That is, if genes were present in multiple copies, then shotgun cloning would suffice. However, if single copy genes were sought, then shotgun cloning was insufficient, and it would be necessary to combine preliminary enrichment with an amplification process.

*Arsenyan et al.* accomplished the preliminary enrichment of the 5S RNA gene by capture of the individual (+) and (-) strands from a sample containing denatured rat liver DNA fragments on solid supports (oligo(dT) cellulose or 5S cDNA-cellulose) having complementary capture probes bound thereto. The strands were separated from the sample, annealed, cloned into *E. coli* and amplified by growing the transformants.

*Arsenyan et al.* provide express motivation to purify target DNA from a sample by capture on a solid support as a preliminary step to amplification. Moreover, and significantly, *Arsenyan et al.* specifically refer to the product of the cloning step as “amplified” DNA. Thus, the motivation is provided to combine target capture with any form of amplification, including *in vitro* amplification. This is consistent with reissue applicants’ own definition of amplification (col. 2, ll. 9-19), which equates all forms of amplification, provided only that they produce additional target molecules or target-like molecules.

*Syvanen et al., Nucleic Acids Res., 14(12):5038-5048 (1986)* provide further motivation to combine target capture with target amplification by stating that “the sensitivity of the [sandwich hybridization] method can be increased ... by amplifying the target DNA” and referring to a reference that describes PCR amplification. (p. 5044, ll. 11-13.)

REISSUE LITIGATION

**D. Summary And Application Of The Prior Art To The Claims.**

In view of the foregoing discussion of the prior art, Protestor submits that claims 1-59 of the reissue application are unpatentable under 35 U.S.C. §103 because they are obvious over *Josephson*, *Whitehead*, *Polsky-Cynkin et al.* or *Ranki* taken with *Feinberg et al.*, *Blumenthal*, *Mullis* or *Gaubatz et al.*, in view of *Brown et al.*, *Arsenyan et al.* or *Syvanen et al.* Each of *Josephson*, *Whitehead*, *Polsky-Cynkin et al.* and *Ranki* disclose the capture of target polynucleotides on solid supports and separation of the support and bound target from the sample. Each of *Feinberg et al.*, *Blumenthal*, *Mullis* and *Gaubatz et al.* disclose *in vitro* amplification methods. *Brown et al.* provide motivation to combine target capture on solid supports with amplification. *Arsenyan et al.* and *Syvanen et al.* provide additional motivation to combine target capture on solid supports with amplification.

Claim 1 is made obvious by a combination of these references that includes any one of the cited target capture references and any one of the cited *in vitro* amplification references, in view of the motivation provided by *Brown et al.* and/or *Arsenyan et al.* to combine these steps.

Claims 2 and 8 recite a “retrievable” support. Both *Josephson* and *Whitehead* disclose supports that are retrievable. *Polsky-Cynkin et al.* disclose the use of a retrievable support in a hybridization assay that includes the detection step of claim 8.

Claims 3 and 9 recite the inclusion of a probe on the solid support, which is also disclosed in *Josephson*, *Whitehead*, *Polsky-Cynkin et al.* and *Ranki et al.*

REISSUE LITIGATION

Claims 4-6, 10-12, 17, 18, 29-33, 35-37, 39 and 40 are dependent claims that recite the use of various polymerases to amplify the target. The use of such polymerases to amplify target sequences is disclosed in *Feinberg et al.*, *Blumenthal, Mullis* and *Gaubatz et al.*

Claim 7 is directed to a method of detecting the target polynucleotide and recites the additional step of detection. *Polsky-Cynkin et al.* and *Ranki* disclose hybridization assays that involve a detection step. Moreover, *Josephson* and *Whitehead* both indicate that the target capture particles disclosed therein can be used in binding assays. These would necessarily include a detection step.

Claims 13, 14 and 16 add the limitation that the amplified polynucleotide is contacted with a label or labeled probe, which is obvious in view of *Polsky-Cynkin et al.*, who disclose a radiolabeled probe (p. 1439, col. 2); *Ranki* who discloses a labeled probe (col. 6, ll. 10-35; col. 7, ll. 20-23 and ll. 35-40) for detection in an assay; or *Josephson*, who discloses a variety of labels (col. 15, ll. 52-58).

Claim 19 is directed to a method of detection that recites the additional step of contacting the amplified target with a second solid support and a detection probe. Claim 15, which is dependent on claim 7, contains essentially the same limitation. The use of a second capture probe to separate the amplified target and detection probe from the other components of the amplification reaction would be obvious in view of *Josephson*, *Whitehead* and *Ranki*.

Claims 20-26 are directed to “kits” for carrying out the claimed methods. Since the methods are obvious for reasons previously stated and the reagents for carrying out the methods

REISSUE LITIGATION

are well known, the mere assemblage of those reagents into a "kit" for carrying out the method cannot confer patentability.

Independent claims 27, 28, 34 and 38 are directed to methods of amplification or detection that recite the use of a nucleic acid probe that is capable of binding to the target nucleic acid as well as to the solid support, thereby providing the means for binding the target to the support. In claims 27 and 28, the probe is first allowed to hybridize to the target before contacting it with the solid support. In claims 34 and 38, the probe, target and solid support are brought into contact in a single step. These claims are all obvious over the references cited above in connection with claim 1, further in view of *Syvanen et al.* Each of *Josephson, Whitehead, Polksy-Cynkin et al.* and *Ranki* disclose the use of a nucleic acid probe that binds the target polynucleotide and the solid support. *Syvanen et al.* teach the advantage of allowing the interaction of the capture probe and target to occur in solution. *Syvanen et al.* disclose a hybridization assay in which the target nucleic acid is captured on a solid support (agarose beads) by the use of a capture probe capable of hybridizing to the target and binding the agarose beads through a biotin-avidin interaction. The capture probe and target are allowed to hybridize in solution prior to capture on the solid support. The advantages of allowing the capture probe to interact with the target in solution are specifically pointed out at pages 5042-5043 ("Kinetics of the reaction"). *Arsenyan et al.* disclose a probe (poly-A tailed 5S rRNA) that binds to both the target polynucleotide (5S DNA) and the support (oligo-dT) by nucleic acid hybridization.

Claims 41-59 are new claims presented for the purpose of reissue. All are dependent on claims in the issued '338 patent.

## REISSUE LITIGATION

Claims 41, 47, 53 and 56-59 recite that “the target polynucleotide is amplified *in vitro* to produce a multitude of amplification products.” Similarly, claims 54 and 55, which are dependent upon kit claims 20 and 24, recite that the “means for amplifying provide for *in vitro* amplification of the target polynucleotide to produce a multitude of polynucleotide amplification products.” These limitations cannot confer patentability on otherwise unpatentable claims, since *Feinberg et al.*, *Mullis* and *Gaubatz et al.* disclose *in vitro* amplification methods that produce a multitude of amplification products.

Claims 42, 45, 48 and 51 recite that the *in vitro* amplification is linear or exponential. Claims 43 and 49 further limit the amplification to exponential amplification. *Feinberg et al.* discloses *in vitro* amplification that is linear. *Gaubatz et al.* indicate (p. 180, col. 1) that their strand displacement method of reproducing polynucleotides exhibits an exponential phase. *Mullis* discloses *in vitro* amplification methods that are exponential. While Protestor questions whether the use of Q $\beta$  replicase enables *in vitro* exponential amplification as described in the ‘338 disclosure (Example 7), to the extent that reissue applicants rely on this method to support such amplification, it is disclosed in *Blumenthal*.

Claims 44 and 50 recite that the target polynucleotide is amplified with a polymerase and at least one oligonucleotide primer. *Feinberg et al.*, *Mullis* and *Gaubatz et al.* each disclose amplification using a polymerase and at least one oligonucleotide primer.

REISSUE LITIGATION

Claims 46 and 52 each recite the use of more than one polymerase to perform amplification. This limitation is made obvious by the *Gaubatz et al.* disclosure that uses a reverse transcriptase to synthesize first-strand cDNA followed by DNA polymerase I (Klenow) to synthesize second strand cDNA (p. 176, col. 2) and for strand displacement (Fig. 1).

**In summary**, based on the foregoing discussion, Protestor submits that:

- Claims 1, 7, 19, 20 and 24 are obvious over any one of *Josephson, Whitehead,*

*Polsky-Cynkin et al.* or *Ranki* combined with any one of *Feinberg et al., Blumenthal, Mullis* or *Gaubatz et al.*, in view of *Brown et al.* or *Arsenyan et al.* Dependent claims 2-5, 8-11, 13-18, 21, 22, 25, 41, 42, 45, 47, 48, 51, 53, 54, and 55 are obvious over the same references.

- Dependent claims 6, 12, 23, 26, 44, and 50 are obvious over any one of

*Josephson, Whitehead, Polsky-Cynkin et al.* or *Ranki* combined with any one of *Feinberg et al., Mullis* or *Gaubatz et al.*, in view of *Brown et al.* or *Arsenyan et al.*

- Dependent claims 43 and 49 are obvious over any one of *Josephson, Whitehead,*

*Polsky-Cynkin et al.* or *Ranki* combined with *Mullis* or *Gaubatz et al.*, in view of *Brown et al.* or *Arsenyan et al.*

- Dependent claims 46 and 52 are obvious over any one of *Josephson, Whitehead,*

*Polsky-Cynkin et al.* or *Ranki* combined with *Gaubatz et al.*, in view of *Brown et al.* or *Arsenyan et al.*

REISSUE LITIGATION

- Claims 27, 28, 34 and 38 are obvious over any one of *Josephson, Whitehead, Polsky-Cynkin et al.* or *Ranki* combined with any one of *Feinberg et al., Blumenthal, Mullis* or *Gaubatz et al.*, in view of *Brown et al., Arsenyan et al.* or *Syvanen et al.* Dependent claims 29-30, 32, 35, 36, 39 and 56-59 are obvious over the same references.
- Dependent claims 31, 33, 37, and 40 are obvious over any one of *Josephson, Whitehead, Polsky-Cynkin et al.* or *Ranki* combined with any one of *Feinberg et al., Mullis* or *Gaubatz et al.*, in view of *Brown et al., Arsenyan et al.* or *Syvanen et al.*

P05W005-00000000

**II. ARGUMENTS MADE BY THE APPLICANTS IN THE PROSECUTION OF THE '338 PATENT CANNOT OVERCOME AN OBVIOUSNESS REJECTION.**

In January 1997, the Examiner rejected the claims of the '080 application over a combination of references showing solid phase target capture with references showing amplification by PCR. In response, the applicants put forth an essentially two-pronged reply. First, applicants argued that the prior art provided no expressed motivation to combine the teachings of target capture and PCR. See, e.g., Examiner's Interview Summary, paper no. 14. Second, applicants sought to focus discussion on PCR amplification, asserting that their invention solved previously unrecognized problems with PCR and represented an improvement of the PCR process. Neither of applicants' arguments is sufficient to overcome an obviousness rejection.

## REISSUE LITIGATION

Applicants' first argument that the prior art provided no motivation to combine target capture and amplification is clearly refuted by the *Brown et al.* and *Arsenyan et al.* references, discussed above, which expressly suggest such combination. Moreover, the suggestions in *Brown et al.* and *Arsenyan et al.* to combine target capture with amplification render moot applicants' second argument regarding the asserted solution of unsolved problems with PCR amplification and alleged improvements in PCR amplification. *Brown et al.* suggest that small quantities of target polynucleotide can be extracted from a sample by sequence-specific target capture on a solid support and then amplified *in vitro* to produce sufficient quantities for further analysis. As long as some motivation or suggestion to combine prior art references is found in the prior art, the law does not require that the prior art suggest combining them for the same reasons set forth by the inventor. *In re Beattie*, 974 F.2d 1309, 1312, 24 USPQ 2d 1040, 1042 (Fed. Cir. 1992); *In re Kronig*, 539 F.2d 1300, 1304, 190 USPQ 425, 427-428 (CCPA 1976); *In re Lintner*, 458 F.2d 1013, 1016, 173 USPQ 560, 562 (CCPA 1972).

The declaration of Dr. David Persing, filed immediately before allowance of the '338 patent, asserted that applicants had solved unrecognized problems with PCR and improved the PCR process. The reissue applicants' arguments for patentability were so focused on PCR that the Examiner was moved, in her statement of reasons for allowance, to state that "*The claims are drawn to methods of PCR amplification* wherein the target is first separated from the sample by using a support that binds to the target polynucleotide and then amplified." ('080 application, Examiner's Interview Summary, paper 22, emphasis added).

## REISSUE LITIGATION

In fact, PCR is neither disclosed in the specification nor claimed. Clearly the claims are not limited to PCR or to any other form of target-specific amplification. Arguments made by the reissue applicants during prosecution of the '338 patent must be scrutinized in the context of the claims *as actually presented*, not narrow claims containing a non-existent limitation to PCR.

In considering the issue of obviousness, the claims must be given their broadest possible interpretation, within the boundaries imposed by the written description requirement. *In re Baker Hughes Inc.*, \_\_\_ F.3d \_\_\_, 55 USPQ2d 1149, 1152 (Fed. Cir. 2000); *In re Tanaka*, 551 F.2d 855, 859, 193 USPQ 138 (CCPA 1977). Narrow arguments directed to alleged improvements to PCR, in particular, or the solution of unexpected problems with PCR are simply not relevant to consideration of the obviousness references set forth above. To allow claims based on PCR-focused arguments would effectively permit the applicants to base patentability on a limitation that is not present in any claim and is not even disclosed in the specification. Therefore Dr. Persing's statements about PCR cannot overcome an obviousness rejection when the claims also encompass other amplification methods.<sup>5</sup>

One of the primary PCR-focused argument advanced during prosecution of the '080 application was that those skilled in the art would not have been motivated to combine target capture with *PCR* because the problem of non-specific amplification, *i.e.*, amplification of non-target sequences, was not recognized at the filing date of the application. The Persing

---

<sup>5</sup> See also Paragraph 12 of the accompanying declaration of Dr. Michael Harpold, which discusses Dr. Persing's declaration. Dr. Harpold concludes that Dr. Persing inaccurately describes the prior art and implicitly assumes the level of skill in the art at the filing date to be lower than it actually was.

REISSUE LITIGATION

declaration, filed on July 14, 1997, states:

Initially, users and proponents of PCR believed that PCR was **highly specific** and could be made to selectively amplify the desired target in an otherwise complex sample system. Practitioners believed that adequate specificity could be imparted to the amplification by careful selection of the primers used in the amplification so that additional steps for isolating target prior to amplification were not required. (Persing Decl. ¶6) (emphasis added).<sup>6</sup>

Dr. Persing's statements, in contrast to the broad scope of the claims, are confined to

PCR. Such limited statements are irrelevant to the obviousness of the invention. The relevant art must be considered in light of the actual claims, broadly construed -- not claims construed narrowly as if they included a limitation to PCR that they, in fact, do not include. Those skilled in the art would immediately recognize that use of non-specific amplification methods, as taught in the specification and encompassed by the claims, would result in the indiscriminate amplification of polynucleotide sequences in the sample unless some prior enrichment of the

---

<sup>6</sup> Dr. Persing's statement as quoted above is contradicted by applicants' own attorney, Norval Galloway, who acknowledged earlier in the '080 application prosecution that Mullis recognized that non-specific amplification could be a problem with PCR. In responding to a rejection over a combination of references including *Mullis U.S. Patent No. 4,683,202*, Mr. Galloway stated "At the same time, however, Mullis recognized that non-target background nucleic acids might also be amplified in addition to the intended target nucleic acids." Preliminary Amendment and Response to Restriction Requirement, filed December 5, 1995. See also, "*DNA Cleavage Adapter Groomed For Genetic Diagnostics*," *Biotechnology Newswatch* 6 (19):8 (1986), in which Mullis is quoted as recognizing that, despite specific primers, PCR results in "a lot of other things replicating that you don't want" and suggesting combination of PCR with other techniques to improve specificity; and *Orkin, N. Engl. J. Med.* 317(16):1023-5 (1987), which describes the use of elevated temperature in PCR as one approach to the problem of background amplification due to hybridization of primers to non-target sequences (p. 1024, col. 2). Thus, even if the claims were directed to an improved PCR method, the art and applicants' admission establish a recognized need that provides the motivation to combine the references.

## REISSUE LITIGATION

target polynucleotide was performed. The benefit of isolating target prior to amplification would, therefore, be obvious.

Other arguments advanced by the reissue applicants during prosecution of the '080 application are also insufficient to overcome an obviousness rejection. For example, applicants argued that practitioners of hybridization assays were reluctant to use hybridization techniques to purify a target polynucleotide prior to amplification because the binding efficiency of a capture probe to its target is less than 100%. The only support offered for this conclusion is a statement

from a 1993 publication that “[T]o date, there are no published studies that demonstrate efficient capture and detection of fewer than 100 target molecules, …” (Persing decl., ¶13). This statement does not warrant the conclusion drawn by Dr. Persing with regard to the motivation of those skilled in the art at the December 1987 filing date. To the contrary, when viewed in the context of the state of the art in December 1987, this statement indicates a clear motivation to combine target capture and amplification methods. As the prior art cited in Section II.B shows, target capture on solid supports was already being used in hybridization assays by December

1987 (see, *Polsky-Cynkin et al.* and *Ranki*). If, as Dr. Persing asserts, those skilled in the art were concerned about loss of target during the capture step, this concern would provide motivation to employ known amplification procedures following target capture in order to compensate for loss of target, thereby increasing the sensitivity of the assay. Indeed, that is precisely what *Brown et al.* suggest -- using *in vitro* amplification to increase small amounts of target nucleic acid isolated by methods such as target capture on a solid support. Consequently,

REISSUE LITIGATION

the use of amplification was an obvious way to increase the sensitivity of art-known hybridization assays employing target capture.

Finally, the reissue applicants argued, during prosecution of the '080 patent, that the claimed method provided an added benefit that was unexpected before December, 1987, i.e. that separation of the target from the sample prior to amplification removed potential amplification inhibitors. In contrast, Protestor submits that the prior art recognized that there would be an inherent benefit of performing target purification before *in vitro* amplification that relied on polymerase activity and thus provided ample motivation to combine target capture with such amplification. The presence of polymerase inhibitors in biological samples has been known for many years. See, e.g., *DNA Synthesis*, Kornberg, A., Freeman & Co., p.65 (1974) and Burgess, *supra*<sup>7</sup>. Thus those skilled in molecular biology have long recognized the need to purify nucleic acids from samples prior to reproducing them with polymerase. See Maniatis *et al.*, *Molecular Cloning, A Laboratory Manual*, (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1982) Chap. 6, *Extraction, Purification and Analysis of mRNA From Eukaryotic Cells*, pp. 187-196 and Chap. 7, *Synthesis and Cloning of cDNA*, pp. 213-214. Thus, it would have been obvious to one skilled in the art that purification of target polynucleotide by any method, including the art-known target capture methods, would have the beneficial effect of removing

---

<sup>7</sup> Kornberg, a basic text on DNA synthesis, states that the presence of an endonuclease that creates 3'-phosphoryl termini can convert a template primer into an inhibitor that binds polymerase enzyme in an unproductive complex. Burgess also recognized the presence of contaminants in enzymatic reactions (pp. 86-89).

REISSUE LITIGATION

inhibiting substances. It should also be noted that the inventors of PCR recognized that the failure to purify target DNA from a sample could result in inhibition of amplification. *Saiki et al.*, *Nature*, 324: 163-6 (1986), at 164, col. 2

For all of the reasons set forth above, applicants' arguments concerning PCR, and applicants' other arguments, cannot save the broad claims of the reissue application from an obviousness rejection.

**III. CLAIMS 1-8, 10-14, 24-52, 55, 58 AND 59 ARE ANTICIPATED BY PRIOR ART ANTEDATING DECEMBER 21, 1987.**

Claim 1 is anticipated by each of *Arsenyan et al.*, *Gene* 11:97-108 (1980); *Gaubatz et al.*, *Biochim. Biophys. Acta*, 825:175-187 (1985); *Boss et al.*, *J. Biol. Chem.*, Vol. 256:12958-12961 (1981); and *Powell et al.*, *Cell* 50:831-840 (1987).<sup>8</sup>

*Arsenyan et al.* teach that a target polynucleotide (DNA encoding rat 5S ribosomal RNA) can be enriched using target capture prior to amplification. The negative strands of the target

---

<sup>8</sup> For purposes of this section, Protestor has relied on prior art having effective dates earlier than December 21, 1987, the filing date of U.S. application no. 136,920. However, the claims of the reissue application may also be anticipated by European Patent publication no. 0 328 829 A2 and by *Thompson et al.*, *Clin. Chem.* 35/9, 1878-1881 (1989), if the reissue application is not entitled to a priority date before January 31, 1991.

Although reissue applicants may assert that application no. 07/648,468 is entitled to the benefit of the filing date of U.S. application no. 07/644,967, the PTO has previously observed that the '468 application was *not* entitled to the benefit of the filing date of the '967 application (or any earlier application). (Paper No. 11, dated April 25, 1995, at pages 2-3, of application 08/400,657; see also 37 C.F.R. § 1.78(a)(1); *In re Chu*, 66 F.3d 292, 297, 36 USPQ2d 1089, 1093 (Fed. Cir. 1995).) Protestor believes that the issue of the priority date may not be amenable to resolution in this *ex parte* proceeding, because it may require discovery of documents and witnesses that is only available in an *inter partes* proceeding.

REISSUE LITIGATION

DNA were captured by passing them directly over a cellulose column having 5S cDNA covalently bound thereto as a target capture probe (pg. 100, col. 2, para. 2). The positive strands of the target DNA were first hybridized to poly(A)-tailed 5S RNA in solution and this hybrid complex was then captured via hybridization to an oligo(dT)-cellulose column (pg. 100, col. 2, para. 3). The columns were washed to separate the target polynucleotides from the starting material. Following target capture, the eluted positive and negative strands were re-natured, ligated into a cloning vector and transformed into *E. coli*. Growing the transformed *E. coli* necessarily produced a multitude of copies of the target polynucleotide. This multiplication of the target polynucleotide clearly falls within reissue applicants' definition of amplification (col. 2, ll. 9-19). Thus, each of the steps of claim 1 -- capture of the target on a solid support, separation from the sample and amplification -- are disclosed in this reference.<sup>9</sup>

Gaubatz *et al.* purified globin mRNA (the target polynucleotide) by chromatography on oligo(dT)-cellulose (the solid support that binds to the target polynucleotide). The purified mRNA was then converted to double-stranded cDNA containing a hairpin loop using AMV reverse transcriptase to synthesize the first strand and DNA polymerase I (Klenow) to synthesize the second strand. A poly(dC) tail was then added to the 3' end of the cDNA using terminal

---

<sup>9</sup> The reissue applicants imply, at page 12 of the preliminary amendment filed with the reissue application, that it is merely the suggestion of a licensee that the meaning of amplification in the '338 patent includes *in vivo* amplification and cell-free translation. However, the reissue applicants chose this definition in their specification (col. 2, ll. 9-19). In light of the public's right to rely on the existing specification, applicants cannot now avoid the prior art by attempting to imply a narrower definition of that term in the claims. See discussion, *infra*, at footnote 2.

REISSUE LITIGATION

deoxynucleotidyltransferase. The resulting double-stranded cDNA with a single-stranded poly(dC) tail was used as a template for amplification. An oligo(dG)<sub>12-18</sub> annealed to the poly(dC) tail was used to prime strand displacement synthesis, producing an inverted repeat sequence of the double-stranded cDNA. The template was "replicated many times" (see p. 179, col. 2) and the amplification/replication had an exponential phase (see p. 180, col. 3). Thus, Gaubatz *et al.* disclose each of the steps of claim 1.

*Boss et al., J. Biol. Chem., 256:12958-12961 (1981)* describes the isolation of yeast iso-

□ 1-cytochrome c (CYC1) mRNA (the target polynucleotide) by hybridization to cloned CYC1 DNA attached to diazobenzyloxymethyl cellulose powder (the solid support that binds the target). The 5' end of the isolated mRNA was sequenced by hybridizing it to a CYC1-specific □ oligonucleotide primer and enzymatically reproducing the isolated sequence in a dideoxy chain □ termination reaction (i.e., amplification). The multitude of enzymatically produced sequences □ were detected by gel autoradiography. The dideoxy chain termination reaction clearly □ constitutes "amplification" in the '338 patent because it produces "additional target, or target- □ like molecules, or molecules subject to detecting" which are "made enzymatically with □ DNA...polymerases".

*Powell et al.* teach the capture of poly(A)<sup>+</sup> RNA from a sample by one or two cycles of binding to a probe attached to a solid support, *i.e.* oligo(dT) cellulose (see p. 839, col. 1). After the captured RNA was eluted from the column, it was amplified using the polymerase chain reaction (p. 839, col. 1). Accordingly, this reference teaches each step of claim 1.

REISSUE LITIGATION

Claims 2 and 8, which are dependent on claims 1 and 7, respectively, recite the use of a support that is retrievable. Claim 8 further requires that the amplification product be detected. These claims are anticipated by *Boss et al.*, in which CYC1 mRNA was isolated by hybridization to cloned CYC1 DNA attached to diazobenzyloxymethyl cellulose powder, i.e. a retrievable support and the amplification products were detected by autoradiography. *Powell et al.* also teach the use of a retrievable support, i.e., oligo(dT) cellulose. The amplification product was detected using a dot blot hybridization assay. Accordingly, claims 2 and 8 are anticipated by

□ *Powell et al.*

Each of the *Arsenyan et al.*, *Gaubatz et al.*, *Boss et al.* and *Powell et al.* references disclose the use of a probe on the solid support, i.e. an oligo(dT) probe, as claimed in claim 3.

Claim 7, which is directed to a method of detecting a target polynucleotide, recites the same three steps as claim 1, followed by the additional step of detecting the presence of the amplified polynucleotide. *Arsenyan et al.* detected the presence of amplified target polynucleotide by colony hybridization to radioactively labeled 5S RNA. *Gaubatz et al.* detected the amplification product by measuring the amount of tritiated dCTP incorporated during the amplification step. *Boss et al.* detected the amplification product by autoradiography. *Powell et al.* detected the amplified polynucleotide by conducting a dot blot hybridization in which the PCR amplification product was hybridized to radioactively labeled oligonucleotide probes. Therefore Claim 7 is anticipated by each of these references.

Claims 4-6 and 10-12, which depend from claims 1 and 7, respectively, recite that amplification is effected by a polymerase, which can be selected from a group including DNA

REISSUE LITIGATION

polymerase. Reproduction of DNA during the growth of the *E. coli* transformants in *Arsenyan et al.* was performed carried out by DNA polymerase. *Gaubatz et al.* employed both AMV reverse transcriptase and DNA polymerase (Klenow) in the amplification of target sequence. *Boss et al.* employed reverse transcriptase in the dideoxy chain termination reaction. *Powell et al.* employed *Taq* polymerase to amplify target polynucleotide. Accordingly, the limitations of claims 4-6 and 10-12 are fully met by each of the references.

Claims 13 and 14, which are dependent on claim 7, additionally recite that the amplified

polynucleotide is contacted with a label (claim 13), which can be a labeled probe (claim 14). The colony hybridization of the amplified DNA with radioactively labeled 5S RNA in *Arsenyan et al.* meets these limitations. *Powell et al.* used radioactively labeled oligonucleotide probes to detect PCR amplification products.

Claims 24-26 are directed to kits for amplifying a target polynucleotide in a sample comprising means for performing target capture and amplification of the target. In view of the foregoing discussion, it is clear that each of the recited means are disclosed in *Arsenyan et al.*,

*Gaubatz et al.*, *Boss et al.* and *Powell et al.*

Claim 27 is directed to a method of amplifying a target polynucleotide in a sample in which the sample is contacted with a capture probe to form a probe-target complex; the sample is then contacted with a solid support that binds the probe-target complex; the support and bound probe-target complex are separated from the sample; the support and bound probe-target complex is contacted with a second medium; the probe-target complex is released into the second medium; the support is removed from the second medium; and the target is amplified.

REISSUE LITIGATION

*Arsenyan et al.* disclose all of these steps. In *Arsenyan*, a sample containing the (+) strand of 5S DNA target is isolated by contacting it with a poly(A)-tailed 5S RNA probe. The sample containing this probe-target complex is then contacted with a solid support, *i.e.* oligo-dT cellulose, which binds the probe-target complex. The support and bound probe-target complex are separated from the sample by washing the column. The support and bound probe-target complex are contacted with a second medium, *i.e.* elution buffer, into which the probe-target complex is released and the support is removed by allowing the elution buffer to flow out of the

□ column (see p.100, col. 2). After this process is repeated, the isolated DNA is amplified by cloning into *E. coli* to produce a multitude of amplification products in the transformants. Claim 27 is anticipated by *Arsenyan et al.*

□ Claim 28 is directed to a method of detecting a target polynucleotide in a sample which  
□ comprises the steps of claim 27 and the additional step of detecting the presence of the target  
□ polynucleotide. Since *Arsenyan et al.* detects the presence of the target sequence by colony  
□ hybridization of the *E. coli* transformants (p. 101, col. 1), it also anticipates claim 28.

Claims 29-33, which depend from claims 27 and 28, add the limitation that amplification is effected by a polymerase, which may be a DNA polymerase. Since amplification in *E. coli*, as taught in *Arsenyan et al.* is effected by DNA polymerase, these claims are also anticipated by *Arsenyan et al.*

Claim 34 is directed to a method of amplifying target polynucleotide in which the sample medium is contacted with a solid support and a probe which binds to the target polynucleotide and the support; the support and bound target are separated from the sample medium; the support

REISSUE LITIGATION

and bound probe and target are contacted with a second medium; the target polynucleotide is released into the second medium; the support and bound probe are removed from the second medium; and the target is amplified. *Arsenyan et al.*, *Gaubatz et al.*, and *Powell et al.* each disclose processes in which target polynucleotide is contacted with a solid support and a probe. After the sample was contacted with the solid support and probe, allowing the target polynucleotide to bind thereto, the remainder of the sample was separated from the support and bound probe and target polynucleotide by flowing out of the chromatography column. The [redacted] column was then contacted with an elution buffer, *i.e.* a second medium, and the target polynucleotide was released into this medium. The elution buffer containing the released target flowed out of the column, thereby separating the support and bound probe from the elution buffer. In each case, the recovered target polynucleotide was then amplified, as described in [redacted] detail above. In the case of *Boss et al.*, the captured target polynucleotide was separated from the [redacted] sample by washing the cellulose powder having the support and target sequence bound thereto, [redacted] eluting with an elution buffer, *i.e.* a second medium, and precipitating with ethanol. Thus, each [redacted] of these references contains every element of claim 34.

Claims 35-37, which are dependent on claim 34, additionally recite that amplification is effected by the use of a polymerase (claim 35), which can be chosen from a recited group of polymerases (claim 36) that includes DNA polymerase (claim 37). Each of *Arsenyan et al.*, *Boss et al.*, *Gaubatz et al.*, and *Powell et al.* employ a form of DNA polymerase in the amplification step. Accordingly, each of these references anticipates claims 35-37.

## REISSUE LITIGATION

Claim 38 is directed to a method for detecting a target polynucleotide, which comprises the steps recited in claim 34 and the additional step of detecting the amplified polynucleotide. As previously indicated, each of *Arsenyan et al.*, *Boss et al.*, *Gaubatz et al.*, and *Powell et al.* discloses the steps recited in claim 34. Moreover, as discussed above in connection with claim 7, each of these references also discloses the detection of amplified polynucleotide. Consequently, each of the references anticipates claim 38.

Claims 39 and 40, which are dependent on claim 38, recite the additional limitation that

□ amplification is effected by a polymerase (claim 39) or a DNA polymerase (claim 40). Since *Arsenyan et al.*, *Boss et al.*, *Gaubatz et al.*, and *Powell et al.* each employ a DNA polymerase for amplification, these claims are anticipated.

Claim 41, which depends from claim 1, recites that amplification is performed *in vitro* to

□ produce a multitude of polynucleotide amplification products. *Gaubatz et al.*, *Boss et al.* and *Powell et al.* each employ *in vitro* amplification to produce a multitude of amplification products.  
□ Accordingly, each anticipates claim 41.

Claim 42, which depends from claim 41, recites that amplification is linear or exponential. Claim 43 further limits amplification to exponential amplification. *Powell et al.* discloses PCR amplification of the target polynucleotide, an exponential amplification process (*Mullis*, U.S. Pat. No. 4,683,202). The strand displacement amplification method of *Gaubatz et al.* has an exponential phase (see p. 180, col. 1). Consequently, claims 42 and 43 are anticipated.

REISSUE LITIGATION

Claim 44, which is dependent on claim 41, recites that amplification is carried out using a polymerase and at least one oligonucleotide primer. *Powell et al.* discloses amplification by PCR using two primers and a polymerase. The strand displacement method employed by *Gaubatz et al.* and the amplification method of *Boss et al.* each use one oligonucleotide primer and a polymerase. Therefore Claim 44 is anticipated.

Claim 45 further limits claim 44 by reciting that amplification is linear or exponential. As previously indicated, both *Powell et al.* and *Gaubatz et al.* teach exponential amplification and anticipate the claim.

Claim 46, which depends from claim 41, recites the use of more than one polymerase to amplify the target polynucleotide. Amplification of the target sequence by *Gaubatz et al.* employed more than one polymerase. The first stage of amplification involved producing a cDNA from the captured RNA polynucleotide by using AMV reverse transcriptase, which is an RNA-directed DNA polymerase. In the subsequent strand displacement steps of the amplification process, DNA polymerase is used to reproduce the target polynucleotide. Thus, the claim is anticipated.

Claims 47-51 recite the same limitations recited in claims 41-45, respectively, but depend from claim 7, which is directed to methods of detection. Consequently, they differ from claims 41-45 only in that they incorporate the step of detecting the amplified polynucleotide. Since *Gaubatz et al.* and *Powell et al.* each meet all the limitations of claims 41-45 and also describe detection of the amplified polynucleotide (see *supra*), both references anticipate claims 47-51.

REISSUE LITIGATION

Claim 52, which depends from claim 47, recites amplification using more than one polymerase. As discussed above, *Gaubatz et al.* teach the use of more than one polymerase for amplification and anticipate the claim.

Claims 55, 58 and 59, which depend, respectively, on claims 24, 34 and 38, provide the additional limitation that the means for amplification provide for *in vitro* amplification to produce a multitude of amplification products. *Gaubatz et al.*, *Boss et al.*, and *Powell et al.* each describe *in vitro* amplification that produces a multitude of amplification products. Moreover,

each of the references meets all the limitations of claims 24, 34 and 38 (see *supra*). Consequently, claims 55, 58 and 59 are anticipated by these references.

**In summary**, based on the foregoing discussion, Protestor submits that:

- Claims 1, 3-7, 10-12, 24-26 and 34-40 are anticipated by each of *Arsenyan et al.*, *Gaubatz et al.*, *Boss et al.* and *Powell et al.*.
- Claims 2 and 8 are anticipated by *Boss et al.* and *Powell et al.*.
- Claims 13 and 14 are anticipated by *Arsenyan et al.* and *Powell et al.*.
- Claims 27-33 are anticipated by *Arsenyan et al.*.
- Claims 41, 44, 55, 58 and 59 are anticipated by *Gaubatz et al.*, *Boss et al.*, and *Powell et al.*.
- Claims 42, 43, 45 and 47-51 are anticipated by *Gaubatz et al.* and *Powell et al.*.
- Claims 46 and 52 are anticipated by *Gaubatz et al.*.

## REISSUE LITIGATION

### **IV. ALL NEWLY PRESENTED CLAIMS MUST BE REJECTED BECAUSE THEY ARE NOT SUPPORTED BY THE DISCLOSURES OF THE '338 PATENT.**

The reissue application includes new claims 41 to 59, which seek to add various limitations to the amplification step of applicants' method. The new claims depend ultimately from independent claims that were not modified substantively from those of the '338 patent.<sup>10</sup> As discussed above, many of the new claims are directed to embodiments in which the target polynucleotide is "amplified *in vitro* to produce a multitude of polynucleotide amplification products" or in which the amplification is "linear or exponential." Other new claims define "means for" practicing such methods in kits.

Beginning with the filing of the '920 application in December 1987, applicants have consistently defined the term "amplify" very broadly. Applicants' definition literally includes virtually all known ways of producing additional target molecules, target-like molecules, or molecules subject to detection in place of the target molecule (col. 2, ll. 9-19). Applicants' literal definition could be understood to include *in vivo* and *in vitro* amplification, linear and exponential amplification, and target-specific and non-specific amplification that may be

---

<sup>10</sup> Claims 41-46 depend ultimately from claim 1, claims 47-52 depend ultimately from claim 7, claim 53 depends from claim 19 (which was modified to correctly refer to an antecedent term), claim 54 depends from claim 20, claim 55 depends from claim 24, claim 56 depends from claim 27, claim 57 depends from claim 28, claim 58 depends from claim 34, and claim 59 depends from claim 38.

## REISSUE LITIGATION

practiced by using a wide variety of available procedures.<sup>11</sup> Applicants maintained their broad definition of amplification at all times during the prosecution of the '338 patent.

In now seeking to add limitations to the amplification step of the new claims, reissue applicants hope to avoid certain of the prior art references discussed in Sections I-III of this Protest. The prior art references require that the new reissue claims be rejected even if the limitations are considered. Furthermore, the limitations now claimed by reissue applicants are not supported by the disclosures of the '338 patent. The new claims must therefore be rejected

on the basis of the "written description" requirement of 35 U.S.C. § 112 and the requirement of 35 U.S.C. § 251 that a reissue application be for the same "invention disclosed in the original patent," without the addition of new matter.

The reissue application defines the term "amplify" very broadly (col. 2, ll. 9-15), so that the proposed limitations would literally apply to all amplification methods. However, the disclosures actually describe only the combination of target capture with *in vitro* amplification wherein the amplification method is non-specific.

---

<sup>11</sup> Protestor believes that the original claims of the '338 patent, properly construed, do not encompass target-specific amplification in light of the narrow disclosures of the '338 specification, but Protestor reserves more detailed arguments regarding the scope of the original claims for *inter partes* proceedings.

## REISSUE LITIGATION

In their detailed description of the invention, the reissue applicants particularly emphasize the benefits of combining target capture with non-specific amplification. For example, the specification states that:

The sensitivity of the above DNA or RNA target capture methods can be enhanced by amplifying the captured nucleic acids. This can be achieved by *non-specific* replication using standard enzymes (polymerases and/or transcriptases). (Col. 30, ll. 14-18, emphasis added.)

The specification further stresses that non-specific amplification of the purified target

- nucleic acid employs non-specific enzymes or primers, which can replicate substantially any nucleic acid sequence:

Amplification of the target nucleic acid sequences, because it follows purification of the target sequences, can employ *non-specific* enzymes or primers... *Thus no specifically tailored primers are needed for each test, and the same standard reagents can be used, regardless of targets.* (Col. 30, ll. 30-40, emphasis added).

- Other portions of the detailed description also describe target capture combined only with
- non-specific amplification. For example, as shown in "FIGS. 4, 5, and 6, the isolated target is non-specifiably [sic] amplified" (col. 15, ll. 56-58). FIGS. 3 and 4 depict amplification of target DNA ("substantially free of sample impurities, debri[s] and extraneous polynucleotides") using core RNA polymerase (which transcribes non-specifically). (Col. 15, ll. 59-65.) FIGS. 5 and 6 depict amplification of isolated target DNA using DNA polymerase and "non-specific hexamer primers"(col. 16, ll. 10-29, particularly lines 21-23). The specification also describes "the situation where the target is RNA.... [in which] the target RNA can be replicated nonspecifically by denaturing the RNA and subjecting the RNA to an enzyme such as Q $\beta$  replicase or reverse transcriptase" (col. 16, ll. 5-9).

## REISSUE LITIGATION

All of the Examples that include amplification describe *only* non-specific amplification, using methods that were known in the prior art. That is, all of the described embodiments<sup>12</sup> use non-specific amplification of a target polynucleotide that has been captured from the sample. Therefore, taken as a whole, the specification teaches only the combination of target capture and *in vitro* non-specific amplification, despite the Reissue Applicants' broad literal definition of "amplify" at column 2, lines 9-19.

Reissue applicants now seek to add certain limitations to the amplification step of their claims. If applicants' claims are to be narrowed, they must be narrowed in a manner consistent with applicants' actual disclosures in the specification. Therefore, the new claims must be to amplification methods actually disclosed in the specification. For example, any limitation to *in vitro* amplification must be combined with a limitation to non-specific amplification because *in vitro* amplification is not mentioned anywhere in the specification except in connection with non-specific amplification.

35 U.S.C. § 112 requires the specification to contain a written description of the invention that is a full, clear, and concise description of the invention. The written description must be equivalent to the claimed subject matter. *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1571-1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997). The disclosure must permit one skilled in the art to reasonably conclude that the inventor had possession of the invention *as claimed*. *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-4, 19 USPQ2d 111, 1117 (Fed Cir. 1991). With respect to claim limitations, the written description must clearly convey to one

---

<sup>12</sup> Where the examples of the specification reflect the only teaching of the specification, those examples are not merely "preferred embodiments," but constitute the applicant's only disclosed invention. *Wang Laboratories Inc. v. America Online Inc.*, 197 F.3d 1377, 1384, 53 USPQ2d 1161, 1165 (Fed. Cir. 1999); *General American Transportation Corp. v. Cryo-Trans, Inc.*, 93 F.3d 766, 770, 772, 39 USPQ2d 1801, 1803, 1805-06 (Fed. Cir. 1996).

## REISSUE LITIGATION

skilled in the art that the applicant made the invention having those limitations. *Martin v. Mayer*, 823 F.2d 500, 505, 3 USPQ2d 1333, 1337 (Fed. Cir. 1987).

Separately from Section 112, 35 U.S.C. § 251 requires that reissue claims be for the same "invention disclosed in the original patent," without the introduction of new matter. Pursuant to sections 112 and 251, limitations added in the reissue application must be rejected if not supported by, and consistent with, the applicants' actual disclosures as set forth in the '338 patent.

The specification contains only two possible sources for disclosures that can serve to limit applicants' amplification step. Neither source supports the limitations proposed by the new claims of the reissue application.

The first possible source is applicants' definition of the term "amplify." However, applicants have so broadly defined that term that it does not disclose the limitations of reissue applicants' new claims. Applicants are precluded from now modifying their long-standing definition in order to narrow its meaning. While an applicant may choose to define a term for the purposes of its use in an application, the applicant must use the term *consistently* in the specification and claims and any special meaning must also be *consistently* adhered to in determining patentability and validity. *Burlington Industries, Inc. v. Dayco Corp.* , 849 F.2d 1418, 1421, 7 USPQ2d 1158 (Fed. Cir. 1988); 5A *Chisum On Patents* § 18.03[3][c], pp. 18-159 to 18-160 (1999). In this regard, an inventor's right to define the terms used in the application ends when the patent issues and the application acquires its own independent life as a technical disclosure to the public. *Lear Siegler, Inc. v. Aeroquip Corp.*, 733 F.2d 881, 888-889, 221 USPQ 1025, 1031 (Fed. Cir. 1984).

## REISSUE LITIGATION

The second possible source for the new claim limitations is the detailed description of the invention including the Examples contained in the specification. Apparently recognizing that they may not simply change their definition of "amplify," reissue applicants in fact rely on the Examples to support their additional proposed limitations. See Preliminary Amendment and Remarks at p. 10.

While the examples disclose *in vitro* amplification, each of the examples makes this disclosure only in connection with non-specific amplification. In each instance, the *in vitro* amplification method described in the Examples is non-specific amplification. Therefore the only disclosure of *in vitro* amplification is a disclosure of *in vitro* non-specific amplification.

Reading the actual disclosures of the specification, one skilled in the art would discern that applicants' invention was limited to *in vitro* amplification using only methods of non-specific amplification. Although reissue applicants may contend that other forms of amplification (e.g., target-specific amplification) are obvious, no other amplification methods are disclosed in the specification. The adequacy of applicants' disclosure must focus on what the specification *actually discloses*, not what applicants contend might be obvious from the specification. *Lockwood v. American Airlines, Inc.*, 107 F.3d 1565, 1571-1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997).

There are numerous methods of *in vitro* amplification and many of these produce "a multitude of amplification products." To the extent the Examples suggest limitations, they suggest multiple, inseparable limitations. The specification only discloses *in vitro* non-specific amplification. Claims that do not concurrently contain both of these limitations are inherently overbroad. Applicants are not free to now modify their broad definition of "amplify" directly, nor are they now free to indirectly modify that definition by selectively claiming some, but not all, of the limitations suggested by the Examples.

REISSUE LITIGATION

To comply with the requirements of 35 U.S.C. § 112 and § 251, any limitation of the new claims based on the disclosures of the Examples must include a limitation to non-specific amplification. The new claims, as presently stated, are not supported by the actual disclosures of the '338 patent and must be rejected under the "written description" requirement of 35 U.S.C. § 112, first paragraph and the "same invention" requirement of 35 U.S.C. § 251.

**CONCLUSION**

Protestor respectfully requests that the Examiner consider the above remarks when examining the reissue application of the '338 patent. Considered together, the above remarks demonstrate that:

- All claims are invalid as obvious under 35 U.S.C. § 103;
- Many claims are invalid as anticipated under 35 U.S.C. § 102; and
- The claims added to the reissue application should be rejected under the "written description" requirement of 35 U.S.C. § 112, first paragraph and the requirement of 35 U.S.C. § 251 that the reissue application be for the "invention disclosed in the original patent."

Respectfully submitted,

  
Peter R. Shearer  
Reg. No. 28,117

Date: August 1, 2000

Gen-Probe Incorporated  
10210 Genetic Center Drive  
San Diego, California 92121  
Telephone: (858) 410-8920  
Facsimile: (858) 410-8637